Vivos Therapeutics Insiders Bulk Buy 1.045 Million Shares at $1.34—A Bullish Bet Amid Volatility

Insider Buying Spree Signals Confidence Amid Volatility

The March 31, 2026 Form 4 filing shows managing director Michael C. Skaff and his affiliated entities purchasing roughly 1.045 million shares of Vivos Therapeutics common stock at $1.34 each, increasing his holdings to 1.354 million shares. In addition, the same day the same parties bought a combined 2.713 million shares in warrants—both Series A and Series B common‑stock warrants and a pre‑funded warrant—at the same price. The purchases were executed at a price only modestly above the closing price of $1.32, indicating that the insiders are confident the stock will rebound from its recent trough.

What the Moves Mean for Investors

For a company whose shares have skidded 48 % year‑to‑date and whose 52‑week low sits at $1.085, the infusion of capital from insiders is a bullish signal. It demonstrates that those with the most intimate knowledge of Vivos’s operational plans feel the current price underestimates future prospects. The simultaneous acquisition of warrants also suggests an expectation of upside: if the company’s sleep‑disordered‑breathing platform gains traction or the acquisition of The Sleep Center of Nevada pays off, the warrants could be exercised at a lower conversion price than the market, providing additional value to the holders.

Contextualizing the Broader Insider Activity

While the most recent insider transaction is a buy, the company‑wide data show a single holding by G. C. Johnson of 3,997 shares as of February 14, 2026. The lack of recent selling or large block trades from other insiders reinforces the notion that Vivos’s leadership is not attempting to hedge out of a potentially undervalued asset. Moreover, the social‑media sentiment around the stock—rated +13 on a scale of ±100—and a buzz level of 59 % indicate growing interest, though still below the average intensity. In a market where the stock has posted a 15.79 % weekly gain yet a -6.38 % monthly decline, these data points collectively paint a picture of cautious optimism.

Implications for the Company’s Future

Vivos is navigating a challenging period: a late filing for its 2025 10‑K, rising operating expenses from its Nevada acquisition, and a negative P/E ratio of -0.58. Yet the insiders’ willingness to invest $1.34 per share suggests confidence in the long‑term trajectory of its technology platform. For investors, this could mean a potential rally if the company’s strategy—expanding sleep‑center testing and treatment—produces incremental revenue growth and margin improvement. However, the low market cap ($13.5 million) and the company’s thin cash position warrant close monitoring; a sharp reversal in sentiment or a failed integration could still trigger a steep decline.

Bottom Line for Investors

In short, the bulk insider purchases at a price marginally above the current market level signal that management believes the stock is undervalued relative to its future prospects. This activity, coupled with a modest but growing social‑media buzz, may presage a short‑term rally if Vivos delivers on its clinical and operational milestones. Savvy investors should weigh these insider signals against the company’s cash burn and recent regulatory delays, but the insider buying trend certainly warrants a more attentive look at Vivos Therapeutics as it strives to turn its sleep‑disorder technology into a sustainable revenue engine.